GATAD2A is a transcriptional repressor and core component of the NuRD (nucleosome remodeling and deacetylase) complex that regulates chr19 structure through histone deacetylation and ATP-dependent remodeling 12. It enhances MBD2-mediated transcriptional repression, with efficient activity requiring its partner protein GATAD2B 12. GATAD2A interacts with chr19 remodeling subunits CHD3, CHD4, and CHD5 within the NuRD complex 3. The protein is phosphorylated by CDKL5 kinase in neuronal cells 4 and undergoes O-GlcNAc modification during cellular senescence 5. Disease relevance is substantial. De novo GATAD2A variants cause a neurodevelopmental disorder featuring global developmental delay, structural brain defects, and craniofacial dysmorphology, expanding the NuRDopathies family 3. GATAD2A is a prioritized causal gene in schizophrenia across diverse ancestry populations 6. ZMYND8 variants associated with intellectual disability disrupt GATAD2A interaction 7. Additionally, dysregulated GATAD2A expression promotes tongue squamous cell carcinoma progression through a ceRNA regulatory pathway 8, and GATAD2A modification promotes senescence-associated transcriptional programs relevant to tumorigenesis 5. These findings establish GATAD2A as a critical epigenetic regulator with significant roles in neurodevelopment and disease pathogenesis.